ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 98.64M +446.2% |
| Revenue (ttm) | n/a |
| Net Income | -39.72M |
| EPS | -22.61 |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,768 |
| Open | 11.35 |
| Previous Close | 11.10 |
| Day's Range | 10.79 - 11.50 |
| 52-Week Range | 6.27 - 39.75 |
| Beta | -0.16 |
| Analysts | Strong Buy |
| Price Target | 42.67 (+287.91%) |
| Earnings Date | May 13, 2026 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PMN stock is "Strong Buy." The 12-month stock price target is $42.67, which is an increase of 287.91% from the latest price.
News
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's dise...
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in ear...
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)
Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disea...
ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Enrollment in a robust phase 1b Alzheimer's trial is complete, with interim and final data expected this year. The proprietary EpiSelect platform enables highly selective targeting of toxic oligomers, aiming for improved efficacy and safety. Strong financing and high retention support a pivotal year.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque
ProMIS Neurosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference
The conference highlighted progress in a phase I-B Alzheimer's trial, with enrollment on track and interim safety and biomarker data expected next year. The lead antibody targets toxic oligomers, aiming for superior safety and efficacy, and may advance rapidly to phase III if results are positive.
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial ProMIS on track to leverage new plasma...
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
ProMIS Neurosciences Announces Reverse Stock Split
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) an...
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim data in Q2 ...
ProMIS Neurosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
A novel antibody targeting toxic amyloid beta oligomers in Alzheimer’s is in a robust phase 1b trial, with interim biomarker data expected mid-next year and final results by year-end. The approach aims to improve efficacy and safety by avoiding plaque and ARIA, drawing strong industry interest.
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's diseas...
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310 Cambridge, Massachusetts, Oct. 22, ...
ProMIS Neurosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A novel antibody therapy targeting toxic amyloid beta oligomers in Alzheimer's is advancing through a robust Phase Ib trial, showing strong safety and no ARIA cases so far. Interim results are expected in Q2 next year, with a potential for rapid progression to Phase III.
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 12...
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Ov...
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference
Presentation to highlight the Company's proprietary protein-misfolding platform, EpiSelect TM , used to develop PMN310 Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and...
ProMIS Neurosciences Announces Private Placement Financing
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million $3 million private financing plus an additional $9...
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer's Disease CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Na...
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
CAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic an...
ProMIS Neurosciences Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Alzheimer's disease remains a major unmet need due to modest efficacy and significant side effects of current therapies, especially ARIA. A novel antibody, PMN-310, selectively targets toxic amyloid oligomers, aiming to improve efficacy and safety, with phase 1B interim results expected next year.
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, ...